HealthQuill Impairment Loss
June 27, 2024: Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss of 5.7 Danish crowns or $817 million in the second quarter of this year.
Drugs Health Pharma

Novo’s end-stage hypertension trial drug fails, $817m impairment loss

Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.

Read More